Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COM
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
29,045,474
-
Shares change
-
-727,853
-
Total reported value, excl. options
-
$537,618,213
-
Value change
-
-$12,626,294
-
Put/Call ratio
-
140%
-
Number of buys
-
48
-
Number of sells
-
-59
-
Price
-
$18.51
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q1 2021
137 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q1 2021.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29,045,474 shares
.
Largest 10 shareholders include HILLHOUSE CAPITAL ADVISORS, LTD. (2,920,023 shares), VANGUARD GROUP INC (2,803,047 shares), BAKER BROS. ADVISORS LP (2,799,577 shares), PICTET ASSET MANAGEMENT LTD (2,487,233 shares), BlackRock Inc. (2,250,611 shares), STATE STREET CORP (1,414,782 shares), AMERIPRISE FINANCIAL INC (1,371,430 shares), Avidity Partners Management LP (1,330,700 shares), JANUS HENDERSON GROUP PLC (1,126,902 shares), and CITADEL ADVISORS LLC (1,021,723 shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.